TY - JOUR
T1 - Antidepressant effect of the translocator protein antagonist ONO-2952 on mouse behaviors under chronic social defeat stress
AU - Nozaki, Kanako
AU - Ito, Hikaru
AU - Ohgidani, Masahiro
AU - Yamawaki, Yosuke
AU - Sahin, Ezgi Hatice
AU - Kitajima, Takashi
AU - Katsumata, Seishi
AU - Yamawaki, Shigeto
AU - Kato, Takahiro A.
AU - Aizawa, Hidenori
N1 - Funding Information:
This research was supported by funds from the Kato Memorial Bioscience Foundation ; by a Grant-in-Aid for Scientific Research on Innovative Areas ( KAKENHI-JP26112010 & JP19H05723 to HA, JP16H06403 to TAK) and a Grant-in-Aid for Challenging Exploratory Research ( KAKENHI-JP17K19459 to HA) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) and a Grant-in-Aid for ‘ Integrated Research on Depression, Dementia and Development Disorders ( JP18dm0107093h0003 & JP18dm0107095 )’ carried out under the Strategic Research Program for Brain Sciences by AMED to SY.
Publisher Copyright:
© 2019 Elsevier Ltd
PY - 2020/1/1
Y1 - 2020/1/1
N2 - In preclinical models, it has been reported that social defeat stress activates microglial cells in the CNS. Translocator protein 18 kDa (TSPO) is a mitochondrial protein expressed on microglia in the CNS that has been proposed to be a useful biomarker for brain injury and inflammation. We hypothesized that a TSPO antagonist, ONO-2952, would inhibit the neuroinflammation induced by microglial hyperactivation and associated depressive-like behaviors. An in vitro analysis showed that ONO-2952 suppressed the release of pro-inflammatory cytokines and mitochondrial reactive oxygen species in cultured microglia stimulated by lipopolysaccharide. In mice submitted to chronic social defeat stress, microglia predominantly expressed TSPO in limbic areas implicated in depressive-like behaviors, including the amygdala, ventral hippocampus and nucleus accumbens, in which an increase in the production of pro-inflammatory cytokines in vivo were associated. Treating animals with ONO-2952 during chronic social defeat stress ameliorated impairments in social avoidance and anxiety-like behaviors and suppressed pro-inflammatory cytokine production, suggesting that ONO-2952 exerted an anti-stress effect in this animal model of depression. Thus, targeting TSPO as a candidate for the development of antidepressants that reduce susceptibility to chronic stress could pave the way toward therapeutic interventions for relapse prophylaxis in depression.
AB - In preclinical models, it has been reported that social defeat stress activates microglial cells in the CNS. Translocator protein 18 kDa (TSPO) is a mitochondrial protein expressed on microglia in the CNS that has been proposed to be a useful biomarker for brain injury and inflammation. We hypothesized that a TSPO antagonist, ONO-2952, would inhibit the neuroinflammation induced by microglial hyperactivation and associated depressive-like behaviors. An in vitro analysis showed that ONO-2952 suppressed the release of pro-inflammatory cytokines and mitochondrial reactive oxygen species in cultured microglia stimulated by lipopolysaccharide. In mice submitted to chronic social defeat stress, microglia predominantly expressed TSPO in limbic areas implicated in depressive-like behaviors, including the amygdala, ventral hippocampus and nucleus accumbens, in which an increase in the production of pro-inflammatory cytokines in vivo were associated. Treating animals with ONO-2952 during chronic social defeat stress ameliorated impairments in social avoidance and anxiety-like behaviors and suppressed pro-inflammatory cytokine production, suggesting that ONO-2952 exerted an anti-stress effect in this animal model of depression. Thus, targeting TSPO as a candidate for the development of antidepressants that reduce susceptibility to chronic stress could pave the way toward therapeutic interventions for relapse prophylaxis in depression.
UR - http://www.scopus.com/inward/record.url?scp=85074890237&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074890237&partnerID=8YFLogxK
U2 - 10.1016/j.neuropharm.2019.107835
DO - 10.1016/j.neuropharm.2019.107835
M3 - Article
C2 - 31682855
AN - SCOPUS:85074890237
SN - 0028-3908
VL - 162
JO - Neuropharmacology
JF - Neuropharmacology
M1 - 107835
ER -